Filing Flows › Sight Sciences (SGHT) › How it makes money
How Sight Sciences (SGHT) makes money
Sight Sciences (SGHT) made $24.9M of revenue in the third quarter 2026 (Q3 2026), +25% from a year earlier. Surgical Glaucoma brought in $21.0M (84%); Dry Eye brought in $3.9M (16%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Surgical Glaucoma | $21.0M | 84.4% | +2% | +7% |
| Dry Eye | $3.9M | 15.6% | +45% | 21× |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $24.9M | 100.0% |
| Income tax | $11K | 0.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $24.9M | +25% |
| Q2 2026 | $23.4M | +20% |
| Q1 2026 | $19.7M | +12% |
| Q4 2025 | $20.4M | +7% |
| Q3 2025 | $19.9M | -1% |
| Q2 2025 | $19.6M | -8% |
| Q1 2025 | $17.5M | -9% |
From Sight Sciences' 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Sight Sciences make money?
Sight Sciences (SGHT) made $24.9M of revenue in the third quarter 2026 (Q3 2026), +25% from a year earlier. Surgical Glaucoma brought in $21.0M (84%); Dry Eye brought in $3.9M (16%).
What is Sight Sciences' biggest business?
Surgical Glaucoma: $21.0M in the third quarter 2026, 84% of revenue, +7% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.